ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC

ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC

Abstract Osimertinib is a third-generation tyrosine kinase inhibitor clinically approved for first-line treatment of EGFR-mutant non-small cell lung cancer (NSCLC) patients. Although an impressive drug response is initially observed, in most of tumors, resistance occurs after different time and an a...

Full description

Bibliographic Details
Main Authors: Caterina De Rosa, Viviana De Rosa, Concetta Tuccillo, Virginia Tirino, Luisa Amato, Federica Papaccio, Davide Ciardiello, Stefania Napolitano, Giulia Martini, Fortunato Ciardiello, Floriana Morgillo, Francesca Iommelli, Carminia Maria Della Corte
Format: Article
Language:English
Published: Nature Portfolio 2024-01-01
Series:Scientific Reports
Online Access:https://doi.org/10.1038/s41598-023-50568-5

Internet

https://doi.org/10.1038/s41598-023-50568-5

Similar Items